VOYA Investment Management’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-16,670
| Closed | -$2.87M | – | 2852 |
|
|
2021
Q3 | $2.87M | Sell |
16,670
-342
| -2% | -$44.7K | 0.01% | 1028 |
|
|
2021
Q2 | $2.13M | Buy |
17,012
+578
| +4% | +$72.9K | ﹤0.01% | 1168 |
|
|
2021
Q1 | $2.23M | Sell |
16,434
-1,061
| -6% | -$137K | ﹤0.01% | 1131 |
|
|
2020
Q4 | $2.24M | Sell |
17,495
-909
| -5% | -$107K | ﹤0.01% | 1089 |
|
|
2020
Q3 | $2.07M | Buy |
18,404
+1,302
| +8% | +$130K | ﹤0.01% | 1019 |
|
|
2020
Q2 | $1.63M | Sell |
17,102
-5,168
| -23% | -$498K | ﹤0.01% | 1090 |
|
|
2020
Q1 | $2M | Buy |
22,270
+330
| +2% | +$25.7K | 0.01% | 953 |
|
|
2019
Q4 | $1.16M | Buy |
21,940
+4,465
| +26% | +$204K | ﹤0.01% | 1369 |
|
|
2019
Q3 | $690K | Hold |
17,475
| – | – | ﹤0.01% | 1549 |
|
|
2019
Q2 | $718K | Buy |
17,475
+644
| +4% | +$26.7K | ﹤0.01% | 1547 |
|
|
2019
Q1 | $784K | Buy |
16,831
+257
| +2% | +$11.3K | ﹤0.01% | 1502 |
|
|
2018
Q4 | $722K | Buy |
16,574
+496
| +3% | +$24.8K | ﹤0.01% | 1499 |
|
|
2018
Q3 | $920K | Hold |
16,078
| – | – | ﹤0.01% | 1459 |
|
|
2018
Q2 | $780K | Buy |
16,078
+67
| +0.4% | +$2.44K | ﹤0.01% | 1528 |
|
|
2018
Q1 | $626K | Hold |
16,011
| – | – | ﹤0.01% | 1662 |
|
|
2017
Q4 | $680K | Buy |
16,011
+1,391
| +10% | +$52.2K | ﹤0.01% | 1661 |
|
|
2017
Q3 | $546K | Hold |
14,620
| – | – | ﹤0.01% | 1811 |
|
|
2017
Q2 | $444K | Buy |
14,620
+3,038
| +26% | +$88K | ﹤0.01% | 1916 |
|
|
2017
Q1 | $307K | Hold |
11,582
| – | – | ﹤0.01% | 2030 |
|
|
2016
Q4 | $296K | Hold |
11,582
| – | – | ﹤0.01% | 2067 |
|
|
2016
Q3 | $419 | Hold |
11,582
| – | – | ﹤0.01% | 1829 |
|
|
2016
Q2 | $394K | Buy |
11,582
+1,584
| +16% | +$51.5K | ﹤0.01% | 1857 |
|
|
2016
Q1 | $264K | Hold |
9,998
| – | – | ﹤0.01% | 2076 |
|
|
2015
Q4 | $488K | Hold |
9,998
| – | – | ﹤0.01% | 1729 |
|
|
2015
Q3 | $249K | Hold |
9,998
| – | – | ﹤0.01% | 2146 |
|
|
2015
Q2 | $316K | Buy |
9,998
+1,047
| +12% | +$33.8K | ﹤0.01% | 2227 |
|
|
2015
Q1 | $341K | Hold |
8,951
| – | – | ﹤0.01% | 2153 |
|
|
2014
Q4 | $349K | Hold |
8,951
| – | – | ﹤0.01% | 2176 |
|
|
2014
Q3 | $271K | Sell |
8,951
-60,466
| -87% | -$1.7M | ﹤0.01% | 2333 |
|
|
2014
Q2 | $2.36M | Buy |
69,417
+1,551
| +2% | +$51.9K | 0.01% | 1030 |
|
|
2014
Q1 | $2.34M | Sell |
67,866
-75,200
| -53% | -$3.39M | 0.01% | 1052 |
|
|
2013
Q4 | $5.67M | Buy |
+143,066
| New | +$3.45M | 0.01% | 765 |
|
VOYA Investment Management's XLRN Position: Q4 2021 in Review
VOYA Investment Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 16,670 shares — an estimated $2.87M sold.
VOYA Investment Management first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $5.67M in Q4 2013. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- VOYA Investment Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- VOYA Investment Management sold 16,670 Acceleron Pharma shares in Q4 2021, an estimated $2.87M.
- VOYA Investment Management first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
- VOYA Investment Management's Acceleron Pharma position peaked at $5.67M in Q4 2013.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on VOYA Investment Management's 13F filing for Q4 2021, filed 14 Feb 2022.